.jpg "Lucas Rodrigues, DVM, PhD photo")
Head of Science
FidoCure/One Health Company
Madison, Wisconsin, United States
Lucas Rodrigues is a veterinarian at FidoCure in charge of investigating the impact of DNA mutations on tumor behavior, evaluating treatment possibilities based on genomic profile and performing scientific research for conferences and manuscript publications. He is an experienced investigator with a deep knowledge in the clinical oncology and molecular biology working in comparative oncology over the last 15 years.
Dr. Rodrigues received his Doctor of Veterinary Medicine from the University Paulista in São Paulo Brazil. After that, he completed his Master and Ph.D. degree from Universidade of São Paulo. He has large experience in molecular biology was acquired during his 5 years of Postdoc at University of Wisconsin-Madison and Penn State University. He worked in several projects supported by funding from The National Cancer Institute (NCI) and other agencies, and has authored at least 10 peer-reviewed journal papers and 4 book chapters. During his Postdoc work his was the first to identified the expression of FZD-6 in osteosarcoma and suggest hat the increased expression suppresses the Wnt/β-catenin signaling pathway, which in turn prevents the differentiation of cells and contributes to osteosarcoma tumor-initiating cells. During his research at Pen State University he prepared the first study to report the critical role of IGF2BP1 in melanoma metastasis, in addition to being the first study to demonstrate the role of any RNA-binding protein in the extracellular vesicle-mediated promotion of metastasis.
Disclosure information not submitted.
Thursday, June 23, 2022
3:15 PM – 3:30 PM CT
Friday, June 24, 2022
11:30 AM – 12:00 PM CT
